Antifungal drugs used for systemic mycoses

Dermatologic Clinics

Volumn 21, Issue 3, 2003, Pages 577-587

  Hay, Roderick J ^a  

^a QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; AMPHOTERICIN B CHOLESTEROL SULFATE; AMPHOTERICIN B LIPID COMPLEX; ANTIFUNGAL AGENT; ASTEMIZOLE; BUTENAFINE; CYCLOSPORIN; DIGOXIN; FLUCONAZOLE; FLUCYTOSINE; INTRALIPID; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; NAFTIFINE; NATAMYCIN; NYSTATIN; RIFAMPICIN; SOMATOSTATIN; SQUALENE MONOOXYGENASE; TACROLIMUS; TERBINAFINE; TERFENADINE; VORICONAZOLE;

ANEMIA; ANGIONEUROTIC EDEMA; ANTIFUNGAL ACTIVITY; ASPERGILLOSIS; BLASTOMYCOSIS; BONE MARROW TOXICITY; BRONCHOSPASM; CANDIDIASIS; CHILL; COCCIDIOIDOMYCOSIS; CRYPTOCOCCOSIS; DIARRHEA; DRUG RESISTANCE; DRUG SCREENING; DYSPEPSIA; FEVER; FUSARIUM; GASTROINTESTINAL SYMPTOM; HEADACHE; HEPATITIS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HISTOPLASMOSIS; HUMAN; HYPOTENSION; INFECTION COMPLICATION; KIDNEY DISEASE; KIDNEY FAILURE; LIVER INJURY; MAST CELL DEGRANULATION; MORTALITY; MUCORMYCOSIS; MYCOSIS; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; POTASSIUM DEPLETION; PRIORITY JOURNAL; RASH; REVIEW; RHABDOMYOLYSIS; RISK ASSESSMENT; SOUTH AMERICAN BLASTOMYCOSIS; STOMACH PH; SYSTEMIC DISEASE; THROMBOCYTOPENIA; THROMBOPHLEBITIS; TOXIC EPIDERMAL NECROLYSIS; URTICARIA;

EID: 0043015821     PISSN: 07338635     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0733-8635(03)00038-X     Document Type: Review

References (38)

1. Wrobel CJ, Chappell ET, Taylor W. Clinical presentation, radiological findings, and treatment results of coccidioidomycosis involving the spine: report on 23 cases. J Neurosurg 2001;95(1 suppl):33-9.
2. Rex JH, Walsh TJ, Sobel JD, et al. Practice guidelines for the treatment of candidiasis. Clin Infect Dis 2000; 30:662-78.
3. Kauffman CA, Hedderwick SA. Treatment of systemic fungal infections in older patients: achieving optimal outcomes. Drugs Aging 2001;18:313-23.
4. Pelz RK, Hendrix CW, Swoboda SM, et al. Double-blind placebo-controlled trial of fluconazole to prevent candidal infections in critically ill surgical patients. Ann Surg 2001;233:542-8.
5. Nwokolo NC, Fisher M, Gazzard BG, Nelson MR. Cessation of secondary prophylaxis in patients with cryptococcosis. AIDS 2001;15:1438-9.
6. Oren I, Haddad N, Finkelstein R, Rowe JM. Invasive pulmonary aspergillosis in neutropenic patients during hospital construction: before and after chemoprophylaxis and institution of HEPA filters. Am J Hematol 2001;66:257-62.
7. Ellis M. Amphotericin B preparations: a maximum tolerated dose in severe invasive fungal infections? Transplant Infect Dis 2000;2:51-61.
8. Espinel-Ingroff A. In vitro fungicidal activities of voriconazole, itraconazole, and amphotericin B against opportunistic moniliaceous and dematiaceous fungi J. Clin Microbiol 2001;39:954-8.
9. Hann IM, Prentice HG. Lipid-based amphotericin B: a review of the last 10 years of use. Int J Antimicrob Agents 2001;17:161-9.
10. Patel R. Amphotericin B colloidal dispersion. Expert Opin Pharmacother 2000;1:475-88.
11. Quilitz RE, Arnold AD, Briones GR, et al. Practice guidelines for lipid-based amphotericin B in stem cell transplant recipients. Ann Pharmacother 2001;35: 206-16.
12. Johansen HK, Gotzsche PC. Amphotericin B vs fluconazole for controlling fungal infections in neutropenic cancer patients. Cochrane Database of Systematic Reviews 2000;(3):CD000239.
13. Krupova Y, Mistrik M, Bojtarova E, Sejnova D, Ilavska I, Krcmery Jr V. Liposomal nystatin (L-NYS) in therapy of pulmonary aspergillosis refractory to conventional amphotericin B in cancer patients. Support Care Cancer 2001;9:209-10.
14. Herbrecht R, Auvrignon A, Andres E, et al. Efficacy of amphotericin B lipid complex in the treatment of invasive fungal infections in immunosuppressed paediatric patients. Eur J Clin Microbiol Infect Dis 2001; 20:77-82.
15. Mocherla S, Wheat LJ. Treatment of histoplasmosis. Semin Respir Infect 2001;16:141-8.
16. Boogaerts M, Maertens J. Clinical experience with itraconazole in systemic fungal infections. Drugs 2001;61(suppl 1):39-47.
17. Boogaerts M, Maertens J, van Hoof A, et al. Itraconazole versus amphotericin B plus nystatin in the prophylaxis of fungal infections in neutropenic cancer patients. J Antimicrob Chemother 2001;48:97-103.
18. Ghannoum MA. Future of antimycotic therapy. Dermatol Ther 1997;3:104-11.
19. Slain D, Rogers PD, Cleary JD, Chapman SW. Intravenous itraconazole. Ann Pharmacother 2001;35: 720-9.
20. Galgiani JN, Catanzaro A, Cloud GA, et al. Comparison of oral fluconazole and itraconazole for progressive, nonmeningeal coccidioidomycosis: a randomized, double-blind trial. Mycoses Study Group. Ann Intern Med 2000;133:676-86.
21. Grant SM, Clissold SP. Fluconazole: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in superficial and systemic mycoses. Drugs 1990;39:877-916.
22. Patton LL, Bonito AJ, Shugars DA. A systematic review of the effectiveness of antifungal drugs for the prevention and treatment of oropharyngeal candidiasis in HIV-positive patients. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2001;92:170-9.
23. Sobel JD, Kauffman CA, McKinsey D, et al. Candiduria: a randomized, double-blind study of treatment with fluconazole and placebo. The National Institute of Allergy and Infectious Diseases (NIAID) Mycoses Study Group. Clin Infect Dis 2000;30:19-24.
24. Kontoyiannis DP, Bodey GP, Mantzoros CS. Fluconazole vs. amphotericin B for the management of candidaemia in adults: a meta-analysis. Mycoses 2001;44: 125-35.
25. Vanden Bossche H, Dromer F, Improvisi I, et al. Antifungal drug resistance in pathogenic fungi. J Med Mycol 1998;36(suppl 1):119-28.
26. Pappas PG, Perfect JR, Cloud GA, et al. Cryptococcosis in human immunodeficiency virus-negative patients in the era of effective azole therapy. Clin Infect Dis 2001;33:690-9.
27. Rollot F, Bossi P, Tubiana R, Caumes E, Zeller V, Katlama C, et al. Discontinuation of secondary prophylaxis against cryptococcosis in patients with AIDS receiving highly active antiretroviral therapy. AIDS 2001;15:1448-9.
28. Ruhnke M, Adler A, Muller FM. Clearance of a fluconazole-resistant Candida albicans strain after switching antifungal therapy and initiation of triple therapy for HIV infection. Clin Microbiol Infect 2000;6:220-3.
29. Baran Jr J, Muckatira B, Khatib R. Candidemia before and during the fluconazole era: prevalence, type of species and approach to treatment in a tertiary care community hospital. Scand J Infect Dis 2001;33:137-9.
30. Minari A, Hachem R, Raad I. Candida lusitaniae: a cause of breakthrough fungemia in cancer patients. Clin Infect Dis 2001;32:186-90.
31. Hossain MA, Ghannoum MA. New investigational antifungal agents for treating invasive fungal infections. Expert Opin Investig Drugs 2000;9:1797-813.
32. Hwang YK, Joo NH, Tee GY, et al. Clinical activity of the new triazole drug voriconazole (UK 109, 496) against disseminated hepatosplenic aspergillosis in a patient with relapsed leukemia. Haematologia (Budap) 2001;31:73-80.
33. Poza G, Montoya J, Redondo C, et al. Meningitis caused by Pseudallescheria boydii treated with voriconazole. Clin Infect Dis 2000;30:981-2.
34. Petraitiene R, Petraitis V, Groll AH, et al. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob Agents Chemother 2001;45:857-69.
35. Heiberg JK, Svejgaard E. Toxic hepatitis during ketoconazole treatment. BMJ 1981;283:825.
36. Petranyi G, Meingassner JG, Mieth H. Antifungal activity of the allylamine derivative, terbinafine, in vitro. Antimicrob Agents Chemother 1987;31:1365-8.
37. Abruzzo GK, Gill CJ, Flattery AM, et al. Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob Agents Chemother 2000;44:2310-8.
38. Onishi J, Meinz M, Thompson J, et al. Discovery of novel antifungal (1,3)-beta-D-glucan synthase inhibitors. Antimicrob Agents Chemother 2000;44:368-77.